These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11669219)

  • 1. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
    Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
    Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R
    N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
    Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
    Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic approach to idiotypic vaccination for B cell lymphoma.
    Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
    Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.
    Haimovich J; Kukulansky T; Weissman B; Hollander N
    Cancer Immunol Immunother; 1999 Feb; 47(6):330-6. PubMed ID: 10203063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
    Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
    Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
    Hsu FJ; Caspar CB; Czerwinski D; Kwak LW; Liles TM; Syrengelas A; Taidi-Laskowski B; Levy R
    Blood; 1997 May; 89(9):3129-35. PubMed ID: 9129015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.